Last updated: February 15, 2026
What Is the Drug Corresponding to NDC 51407-0293?
NDC 51407-0293 refers to Biosimilar Bevacizumab (marketed under the brand name Zirabev), indicated for metastatic colorectal cancer, non-small cell lung cancer, and other malignancies. It is a biosimilar to the reference product Avastin (bevacizumab).
Market Size and Growth Drivers
-
Cancer Therapy Market: The global oncology drugs market was valued at approximately USD 150 billion in 2022 and is projected to grow at a compound annual growth rate (CAGR) of 6.2% through 2027 (source [1]).
-
Biosimilar Adoption: Biosimilars are capturing market share due to lower prices and increased healthcare initiatives to reduce drug costs. Biosimilars accounted for about 27% of the global monoclonal antibody (mAb) market in 2022, expected to reach 50% by 2030 (source [2]).
-
Market Penetration of Bevacizumab Biosimilars: The biosimilar bevacizumab segment is growing. Until 2022, it represented around 15% of the total bevacizumab market, with projections reaching 40% by 2027. The entry of Zirabev and other biosimilars is accelerating this transition.
-
Regulatory Approvals: Zirabev gained FDA approval in July 2019. Its authorized indications align with Avastin, expanding its market reach.
Competitive Landscape
| Product |
Manufacturer |
Year of FDA Approval |
Market Share (2022) |
Price Range (per 100 mg) |
Key Differentiator |
| Zirabev (bevacizumab-bvzr) |
Pfizer |
July 2019 |
Approx. 10-15% globally |
USD 2,500 - 3,000 |
Cost-effective biosimilar alternative |
| Avastin |
Genentech/Roche |
2004 |
Dominates 85-90% |
USD 4,300 - 4,800 |
Original reference biologic |
| Cyramza (ramucirumab) |
Eli Lilly |
2014 |
Competitive segment |
USD 3,200 - 3,600 |
Different mechanism but similar indications |
Note: Actual regional market shares vary; these are global estimates.
Pricing Dynamics
- The retail price of Zirabev is roughly 50-55% lower than Avastin due to biosimilar competition.
- Price projections suggest a continued downward trend in biosimilar costs, driven by increased manufacturing efficiency, market competition, and healthcare policies favoring biosimilar use.
Projected Price Trends (2023-2027)
| Year |
Average Price per 100 mg |
Factors Influencing Price |
| 2023 |
USD 2,500 – 3,000 |
Initial post-entry competition |
| 2024 |
USD 2,400 – 2,900 |
Increased biosimilar adoption |
| 2025 |
USD 2,300 – 2,800 |
Market saturation, cost reduction |
| 2026 |
USD 2,200 – 2,700 |
Price competition intensifies |
| 2027 |
USD 2,100 – 2,600 |
Consolidation, policy influence |
Key Market Challenges and Opportunities
-
Challenges:
- Limited interchangeability policies in certain regions.
- Physician and patient familiarity with original biologics.
- Patent litigations delaying biosimilar market entry in some jurisdictions.
-
Opportunities:
- Growing acceptance among healthcare providers.
- Price advantages leading to wider insurance and government reimbursement.
- Expansion into emerging markets with high cancer burden.
Regulatory and Pricing Policy Factors
- The U.S. biosimilar approval pathway under the Biologics Price Competition and Innovation Act (BPCIA) accelerates biosimilar entry.
- Countries like EU member states and Japan actively promote biosimilar adoption via cost savings and regulatory incentives.
- U.S. CMS has included biosimilars in the Medicare Part B drug pricing negotiations, which could further pressure prices.
Summary of Price and Market Trajectory
- Biosimilar Bevacizumab (Zirabev) is positioned for steady growth from 2023 onward.
- Prices are expected to stabilize around USD 2,100 - 2,600 per 100 mg by 2027, reflecting intensified biosimilar competition and policy support.
- The total market share for Zirabev and similar biosimilars will likely increase, capturing a larger portion of Avastin’s market.
Key Takeaways
- Zirabev, as a biosimilar to Avastin, entered the market in 2019 and has gained market share amid declining prices.
- The global biosimilar monoclonal antibody market is expanding rapidly, driven by cost savings and increased acceptance.
- Price projections indicate a gradual decline over the next five years, stabilizing around USD 2,100–2,600 per 100 mg.
- Market share growth depends on regulatory acceptance, physician adoption, and healthcare policies favoring biosimilars.
- Competitive dynamics primarily favor cost reductions, with biosimilars projected to represent 50% of the bevacizumab market by 2030.
FAQs
Q1: What are the main factors influencing biosimilar prices?
Market competition, manufacturing costs, regulatory policies, patent litigations, and healthcare reimbursement strategies influence biosimilar prices.
Q2: How does Zirabev compare clinically to Avastin?
Zirabev demonstrates biosimilarity in efficacy, safety, and immunogenicity, meeting FDA standards for biosimilars.
Q3: How significant is biosimilar adoption in oncology markets?
In markets like Europe, biosimilars account for over 50% of the monoclonal antibody oncology segment; in the U.S., adoption is increasing but varies regionally.
Q4: What regulatory challenges exist for biosimilars like Zirabev?
Interchangeability designations and patent litigations can delay market expansion and substitution policies.
Q5: Which regions are leading in biosimilar market growth?
Europe and North America are early adopters; Asia-Pacific markets are expanding with increasing regulatory approvals and cost pressures.
Citations
- MarketWatch, "Oncology Drugs Market Size & Trends," 2022.
- IQVIA Institute, "Biosimilar Trends Report," 2022.
[Note: The reference numbers correspond to the inline citations.]
